A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

AstraZeneca has warned that countries must buy more of its cutting-edge medicines or jobs and investment will shift abroad.

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

AstraZeneca (NASDAQ:AZN) on Tuesday said it may face a fine of up to $8 million over suspected unpaid import taxes in China.

AstraZeneca said today it may face a fine of up to $8m over suspected unpaid import taxes in China as the drugmaker works to ...

AstraZeneca may face a fine of up to $8 million in China over suspected unpaid taxes related to the import of its breast ...

Expectations for the full year Core tax rate are unchanged at 18-22% Core EPS increased 21% to $2.49 Five positive Phase III readouts and 13 approvals in major regions since the prior results Pascal ...

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a ...

Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...